23 / 48
Activity of ALK inhibitors in crizo-naive ALK+ patients
Drug
Study
ORR
mPFS
Crizotinib
Phase I PROFILE 1001
Phase II PROFILE 1005
60.8%
59.8%
9.7
8.1
Ceritinib
Phase I ASCEND-1
Phase II ASCEND-3
72%
63%
18.4
11.1
Alectinib
Phase I/II AF-001JP
93.5%
NR
Brigatinib
Phase I/II
100%
34.2m
Lorlatinib
Phase II
90%
NR
Ensartinib
Phase I/II
80% (FISH)- 92% NGS 26.2m
Camidge DR, et al Lancet Oncol 2012. Kim DW, et al. ASCO 2012.Kim DW et al. Lancet Oncol 2016. Felip E et al. ESMO 2016; Tamura
T, et al. J Clin Oncol 2017. Bazhenova L et al. ESMO 2017. Solomon et al WCLC 2017. Horn L et al. Clin Cancer Res 2018